DeuterOncology
ActiveSummary
DeuterOncology has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€2.6m) and a net result of -€3.6m. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 5% of 94 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 1.0% (low).
Overview
Official details
Source: KBO- Status
- Active since 28-09-2020 Normal situation
- Registered office
- 51 active companies are registered at this address 3 started in the 12 months before. Source: KBO register, as of 4 November 2026.
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparations NACE 21100and 1 other
- Establishment unit
- 2.310.808.036 4000 Liège, since 28-09-2020
- Financial year end
- 31 December
- Peppol
- Reachable since 10-03-2026
Board and ownership
- Huerga Sanchez IkerChair
- Newton Biocapital Partners SRL/BVDirector · since 04-02-2021 · permanent representative Pierre Georges DETRIXHE
- NOSHAQ PARTNERS SRL/BVDirector · since 20-12-2022 · permanent representative Sabatel Hélène
- Auditor
- B.D.O bedrijfsrevisoren
- Newton Biocapital I, pricaf privée de droit belge69.63%· score 922025 annual accounts of Newton Biocapital I, pricaf privée de droit belge
- ORSA TECH8.81%· score 9330-06-2025 annual accounts of ORSA TECH
- Holdings
- Shares in 1 company OCTIMET Oncology
Financial position
- Bankruptcy probabilitywithin 12 months
- 1.0%
- Gross margin
- -€3.3m
- ▼ 65.0%
- Loss
- €3.6m
- ▲ 70.3%
- Equity
- -€2.6m
- Total assets
- €688,028
- ▼ 45.9%
- Negative equity on 31-12-2025
Score breakdownraises riskCapped at 59: negative equityLoss of €3.6m, the second in a row (financial year 2025)Negative equity -€2.6mlowers riskSize: total assets €688,028Legal form: public limited companyShow the evidence
Checked score
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro). It does better than 10% of them on solvency, 35% on liquidity, 13% on profitability and 3% on growth.
The bankruptcy probability was computed on 03-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 5 accounts on average 18 days before the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
- Risk: Negative equitydebts exceed assets in financial year 2025 -€2.6m View
- Risk: 5 loss-making years in a rowloss in financial year 2025 -€3.6m View
- Caution: Lower solvency than 95% of companies in pharmaceuticalssector median 48.2% · 94 companies -383.0% View
- Caution: Result fell in 2025from -€2.1m to -€3.6m ▼ 70.3% View
- Board changedlatest change 12-05-2026 · 6 in office 6 joined · 3 left View
- Positive: Filed on time since financial year 2022accounts within the deadline every year 4 years View
Recent changes
- · Gazette deed Reappointment: B.D.O. Bedrijfsrevisoren (statutory auditor)
- · Gazette deed Resignation: VIZIPHAR Biosciences SRL (chair of the board)Appointment: Huerga Sanchez Iker (chair of the board)
- · Gazette deed 5 directors appointed, 5 directors resigningChanges of role: Newton Biocapital Partners BV/SRL (administrateur nbc) and NOSHAQ PARTNERS BV/SRL (administrateur noshaq/investsud tech) · Resignations: VIZIPHAR Biosciences BV/SRL, PERERA Timothy and SAGODIRA Serge · Appointments: HUERGA Iker, DAVIS Kipp Richard Fairchild and DOLAN Alexander Patrick
Comparable companies
These companies have the same main activity as DeuterOncology: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100). They are comparable in size and age: total assets between €148,000 and €4.8m, founded between 2016 and 2023.
| Company | Total assets | Gross margin |
|---|---|---|
| DeuterOncology Liège | €0.7m | -€3.3m |
| Pharma Chemicals France Braine-le-Château | €1.1m | -€0.1m |
| BIOSEUTICA BELGIUM Bastogne | €0.8m | -€0.005m |
| Galenicap Elsene | €1.5m | -€0.4m |
| TAKEAIR Oudenaarde | €1.5m | -€0.2m |
| Novozymatic Kapellen | €0.1m | -€0.06m |
| NeGIO Therapeutics Charleroi | €4.8m | -€0.2m |
Key facts about DeuterOncology
- What is the company number of DeuterOncology?
- The company number of DeuterOncology is 0754.971.388. The VAT number is the same number with BE in front: BE 0754.971.388.
- Where is DeuterOncology based?
- The registered office is at Clos Chanmurly 13, 4000 Liège.Company details
- What does DeuterOncology do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
- What is the legal form of DeuterOncology?
- The legal form of DeuterOncology is Public limited company (NV).
- When was DeuterOncology founded?
- DeuterOncology was founded on 28-09-2020.
- Is DeuterOncology still active?
- Yes, DeuterOncology is an active enterprise in the KBO register.
- What is the turnover of DeuterOncology?
- The annual accounts for financial year 2025 state no turnover.Financials
- Is DeuterOncology profitable?
- In financial year 2025, DeuterOncology made a loss of €3.6m.
- Where can I find the annual accounts of DeuterOncology?
- DeuterOncology filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DeuterOncology due?
- DeuterOncology must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.